MYM Nutraceuticals Announces Rob Gietl as New CEO

Vancouver, B.C., April 28, 2017 – MYM Nutraceuticals Inc. (CSE:MYM) (OTC:MYMMF), a bio-pharmaceutical company, is pleased to announce that the Board of Directors unanimously voted to appoint Rob Gietl as its new Chief Executive Officer. Mr. Gietl is well known for his ability to exponentially grow businesses including the westcoast franchise expansion of Dominos Pizza, where he Consistently grew the annual business to achieve 300+% increases year over year.

Mr. Gietl is a seasoned Business Development and Operations executive with a diverse track record of leading change across all areas of concept creation, brand re-positioning, market penetration, fiscal accountability and efficient execution of business plans. He has grown business effectiveness in an array of sectors and circumstances throughout Canada, consistently aligned with stakeholders goals and values. Mr. Gietl was most recently the Director of Business Development at NRI Global Inc. where he headed up multi million dollar industrial acquisitions, environmental remediation and global sales of reusable assets and commodities. His skills in negotiations and plan development enabled him to leverage partnerships to accelerate expansion and facilitate synergy in execution.

MYM is very pleased to have Mr. Gietl on the team and believe his extensive experience in general management, marketing, and innovation reinforces the company’s bright future. Mr. Gietl will be tasked with driving the expansion of new product offerings and building out new sales teams across the U.S., Canada and internationally.

Mr. Gietl commented, “It is exciting to be joining this dynamic company which is on the verge of attaining fantastic milestones in this rapidly evolving industry. Our focus in the short-term will be completing the build out of our Quebec grow facility and expanding our HempMed product line sales network in Canada, the USA and internationally. We also have many new exciting products in our pipeline, examples ranging from CBD products, CBD beverages and ancillary businesses to the marijuana market.”

Mr. Gietl further commented, “It is my mission, through aggressive growth, organically, acquisitions, additional product lines and new markets to bring the company to the top of our industry to benefit our customers and shareholders.”

Mr. Gietl is replacing current CEO, John Fiteni, who now will be director of Production Operations and Product Development, in which he has very specialized experience. “The shareholders of this company are in good hands,” commented Jonathan Fiteni. “Mr. Gietl brings experience, passion and a unique approach to business our company can only benefit from. This is a huge win for our shareholders and I look forward to working with Rob closely as we set out to build a truly great company. I want to thank my team for all their support over the years and look forward to being a part of a bigger, better MYM Nutraceuticals.”

Pursuant to the Executive Agreement, MYM will issue 500,000 common shares to Mr. Gietl as a signing bonus. The Company shall also issue the Executive 2,000,000 options to purchase Common shares in the capital of the Company at a price of $0.20. The options shall vest quarterly over the two-year Term of this Agreement.
MYM is continuing to negotiate acquisitions of complimentary businesses and assets in the technology, nutraceuticals and CBD nutraceutical sector and is currently in talks with other innovative companies.

About MYM
MYM Nutraceuticals Inc. (CSE:MYM)(OTC:MYMMF)(FRA:OMY) is a public company trading on the Canadian Stock Exchange whose primary focus is developing high-end organic CBD and cannabis supplements and topical products. MYM also has an interest in the development of high-density farming facilities and technologies that allow MYM to expand its brand into the global market.

“Chris Jackson”
Chris Jackson, Director
MYM Nutraceuticals Inc.
This news release may contain forward-looking statements based on assumptions and judgments of management regarding future events or results. Such statements are subject to a variety of risks and uncertainties which could cause actual events or results to differ materially from those reflected in the forward-looking statements. The company disclaims any intention or obligation to revise or update such statements. For a description of the risks and uncertainties facing the Company and its business and affairs, readers should refer to the Company’s Management’s Discussion and Analysis and other disclosure filings with Canadian securities regulators, which are posted on
This news release does not constitute an offer to sell or solicitation of an offer to buy any of the securities described herein and accordingly undue reliance should not be put on such. Neither the Canadian Securities Exchange (CSE or CNSX Markets), nor its Regulation Services Provider (as that term is defined in policies of the CSE), accepts responsibility for the adequacy or accuracy of this release.
This news release does not constitute an offer to sell or a solicitation of an offer to buy any of the securities described herein in the United States. The securities described herein have not been registered under the United States Securities Act of 1933, as amended (the “U.S. Securities Act”), or any state securities law and may not be offered or sold in the “United States”, as such term is defined in Regulation S promulgated under the U.S. Securities Act, unless registered under the U.S. Securities Act and applicable state securities laws or an exemption from such registration requirements is available.